ClinicalTrials.gg

Program

dapiglutide

Also written as “ZP7570”, “Dapiglutide 7.5 mg” and “Dual GLP-1/GLP-2 Receptor agonists”.

Its studies are mostly in Obesity, led by Zealand Pharma.

Furthest: phase 1, since Aug 8, 20234 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zealand Pharma40 open or runningphase 1since Aug 8, 2023May 15, 2019none ahead

Also a collaborator on its studies: Profil Institut für Stoffwechselforschung.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 15, 2019First study: early phase 1 study in HealthyFirst studyNCT03994549 · 64 enrolled · Germany
  2. Oct 20, 2020Early phase 1 study in HealthyNCT04612517 · 40 enrolled · Germany
  3. Aug 8, 2023Phase 1 study in OverweightNCT06000891 · 84 enrolled · Germany
  4. Dec 9, 2024Phase 1 study in OverweightNCT06758583 · 30 enrolled · Germany

TargetBeta

GLP1R →read by rule
“Dapiglutide is a dual Glucagon-like peptide-1-/Glucagon-like peptide-2 Receptor Agonist (GLP-1R/GLP-2RA) in clinical development for weight management.”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06758583Overweight · Germany1CompletedApr 12, 202530
NCT06000891Overweight · Germany1TerminatedFeb 11, 202584
NCT04612517Healthy · GermanyEarly 1CompletedAug 30, 202140
NCT03994549Healthy · GermanyEarly 1CompletedNov 2, 202064

How it is read

Names in the registry

  • “ZP7570”, 2 entries
  • “Dapiglutide 7.5 mg”, 1 entry
  • “Dual GLP-1/GLP-2 Receptor agonists”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.